You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR positive mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Mar 23, 2023

    NSCLC Trial in Shanghai (TY-9591(10mg,40mg) qd. po)

    Recruiting
    • NSCLC
    • TY-9591(10mg,40mg) qd. po
    • Shanghai, China
      Shanghai Chest Hospital
    Nov 7, 2021

    Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 13, 2022

    NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Befotertinib + Icotinib placebo
    • Icotinib + Befotertinib placebo
    • Beijing, China
    • +2 more
    Sep 20, 2023

    NSCLC Trial (Almonertinib Envafolimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Almonertinib Envafolimab
    • (no location specified)
    Sep 10, 2022

    Real-world Data of Afatinib Treatment in First-line Setting and

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Tokyo, Japan
      Nippon Boehringer Ingelheim Co., Ltd.
    Jan 9, 2023

    EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among

    Recruiting
    • Lung Cancer
    • Kuala Lumpur, Malaysia
    • +2 more
    Nov 21, 2022

    Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

    Not yet recruiting
    • Lung Cancer
    • +4 more
    • (no location specified)
    Sep 15, 2023

    Lung Adenocarcinoma Stage III, EGFR Gene Mutation Trial in Shang'ai (Afatinib)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • EGFR Gene Mutation
    • Shang'ai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 27, 2022

    NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Maastricht, Limburg, Netherlands
    • +4 more
    Nov 7, 2022

    Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
      • Moscow, Russian Federation
        Federal State Budgetary Institution National Medical Research Ce
      Mar 29, 2022

      Non Small Cell Lung Cancer Trial in Seoul (Neoadjuvant lazertinib)

      Recruiting
      • Non Small Cell Lung Cancer
      • Neoadjuvant lazertinib
      • Seoul, Korea, Republic of
        Konkuk University Medical Center
      Jul 20, 2022

      NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)

      Recruiting
      • Non-small Cell Lung Cancer
      • +3 more
      • Furmonertinib 160 mg, Q.D.
      • Chongqing, Chongqing, China
      • +2 more
      Sep 16, 2022

      Lung Adenocarcinoma Stage III Trial in Shanghai (HS-10296 (Almonertinib))

      Recruiting
      • Lung Adenocarcinoma Stage III
      • HS-10296 (Almonertinib)
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Mar 17, 2022

      EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

      Not yet recruiting
      • EGF-R Positive Non-Small Cell Lung Cancer
      • +4 more
      • Stereotactic Body Radiation Therapy SBRT
      • Bogotá, Colombia
        CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
      Aug 16, 2023

      Non-Small Cell Lung Carcinoma Trial in Duarte, Stanford, Nashville (drug, biological, other)

      Terminated
      • Non-Small Cell Lung Carcinoma
      • Duarte, California
      • +2 more
      Apr 6, 2022

      NSCLC Trial in Changsha (Furmonertinib)

      Recruiting
      • Non-Small Cell Lung Cancer
      • Changsha, Hunan, China
        Hunan Cancer hospital
      May 19, 2022

      NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

      Completed
      • Carcinoma, Non-Small-Cell Lung
      • Duarte, California
      • +8 more
      Jan 31, 2023

      Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

      Active, not recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • +5 more
      • Laboratory Biomarker Analysis
      • +3 more
      • New Haven, Connecticut
      • +4 more
      Jan 27, 2023

      Metastatic NSCLC Trial in Shanghai (Gentuximab)

      Recruiting
      • Metastatic Non-Small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Chest Hospital
      Jan 24, 2022

      Lung Cancer Trial in Seoul (Osimertinib 80 MG)

      Suspended
      • Lung Cancer
      • Osimertinib 80 MG
      • Seoul, Korea, Republic of
        Samsung medical center
      Jan 13, 2022

      PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

      Recruiting
      • Non Small Cell Lung Cancer
        • Changsha, Hunan, China
          Yongchang Zhang
        Mar 9, 2022